These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
427 related items for PubMed ID: 32307307
1. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan. Nakayama T, Vidor E, Tsuzuki D, Nishina S, Sasaki T, Ishii Y, Mizukami H, Tsuge H. J Infect Chemother; 2020 Jul; 26(7):651-659. PubMed ID: 32307307 [Abstract] [Full Text] [Related]
2. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States. Klein NP, Abu-Elyazeed R, Cheuvart B, Janssens W, Mesaros N. Hum Vaccin Immunother; 2019 Jul; 15(4):809-821. PubMed ID: 30444673 [Abstract] [Full Text] [Related]
4. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Guerra FA, Blatter MM, Greenberg DP, Pichichero M, Noriega FR, Pentacel Study Group. Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896 [Abstract] [Full Text] [Related]
7. Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants. Li Y, Li RC, Ye Q, Li C, Liu YP, Ma X, Li Y, Zhao H, Chen X, Assudani D, Karkada N, Han HH, Van Der Meeren O, Mesaros N. Hum Vaccin Immunother; 2017 Mar 04; 13(3):588-598. PubMed ID: 27768515 [Abstract] [Full Text] [Related]
8. Antibody persistence to diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens, and Haemophilus influenzae type b following primary and first booster with pentavalent versus hexavalent vaccines. Wanlapakorn N, Sarawanangkoor N, Srimuan D, Thatsanathorn T, Thongmee T, Poovorawan Y. Hum Vaccin Immunother; 2024 Dec 31; 20(1):2352909. PubMed ID: 38752802 [Abstract] [Full Text] [Related]
15. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America. López P, Arguedas Mohs A, Abdelnour Vásquez A, Consuelo-Miranda M, Feroldi E, Noriega F, Jordanov E, B Chir S, Zambrano B. Pediatr Infect Dis J; 2017 Nov 31; 36(11):e272-e282. PubMed ID: 28719500 [Abstract] [Full Text] [Related]
18. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial. Melo FIR, Morales JJR, De Los Santos AHM, Rivas E, Vigne C, Noriega F. Pediatr Infect Dis J; 2017 Jun 31; 36(6):602-608. PubMed ID: 28067718 [Abstract] [Full Text] [Related]
19. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel). Johns TL, Hutter GE. Ann Pharmacother; 2010 Mar 31; 44(3):515-23. PubMed ID: 20197476 [Abstract] [Full Text] [Related]